In humans, CB-839, an oral glutaminase inhibitor, has been studied in a phase 2 cancer trial (Clinical Trial NCT 02771626) and could therefore be repurposed for human PAH studies, especially given the results obtained by Bertero et al. in animal models [27]. Here, GLS is linked to pulmonary arterial hypertension.